Lilly's Retatrutide Delivers Double The Weight Loss Of Ozempic, Raising Competitive Stakes For Novo Nordisk (NYSE: NVO)
Patients taking Lilly’s retatrutide shed more than twice the body weight of those on Ozempic, a result that Citi says meaningfully intensifies competitive pressure on Novo Nordisk…
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 30 15:44 ETSource: Foreign Policy Journal
From the source
Read at foreignpolicyjournal.comLilly's Retatrutide Delivers Double The Weight Loss Of Ozempic, Raising Competitive Stakes For Novo Nordisk (NYSE: NVO)
Patients taking Lilly’s retatrutide shed more than twice the body weight of those on Ozempic, a result that Citi says meaningfully intensifies competitive pressure on Novo Nordisk (NYSE: NVO).
